Page 1585 - Williams Hematology ( PDFDrive )

1560 Part XI: Malignant Lymphoid Diseases Chapter 93: Hairy Cell Leukemia 1561

3. Spiers AS, Parekh SJ, Bishop MB: Hairy-cell leukemia: Induction of complete remission 35. Xi L, Arons E, Navarro W, et al: Both variant and IGHV4–34–expressing hairy cell
with pentostatin (2′-deoxycoformycin). J Clin Oncol 2:1336–1342, 1984. leukemia lack the BRAF V600E mutation. Blood 119:3330–3332, 2012.
4. Grever MR, Siaw MF, Jacob WF, et al: The biochemical and clinical consequences of 36. Tiacci E, Schiavoni G, Martelli MP, et al: Constant activation of the RAF-MEK-ERK
2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 57:406–417, pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica
1981. 98:635–639, 2013.
5. Grever MR, Leiby JM, Kraut EH, et al: Low-dose deoxycoformycin in lymphoid malig- 37. Chung SS, Kim E, Park JH, et al: Hematopoietic stem cell origin of BRAFV600E muta-
nancy. J Clin Oncol 3:1196–1201, 1985. tions in hairy cell leukemia. Sci Transl Med 6:238ra71, 2014.
6. Spiers AS, Moore D, Cassileth PA, et al: Remissions in hairy-cell leukemia with pen- 38. Cawley JC: The pathophysiology of the hairy cell. Hematol Oncol Clin North Am
tostatin (2′-deoxycoformycin). N Engl J Med 316:825–830, 1987. 20:1011–1021, 2006.
7. Kraut EH, Bouroncle BA, Grever MR: Pentostatin in the treatment of advanced hairy 39. Foucar K, Falini B, Catovsky D, Stein H: Hairy cell leukaemia, in WHO Classification of
cell leukemia. J Clin Oncol 7:168–172, 1989. Tumours of Haematopoietic and Lymphoid Tissues, 4 ed, edited by Swerdlow SH, Campo
8. Johnston JB, Eisenhauer E, Corbett WE, et al: Efficacy of 2′-deoxycoformycin in hairy- E, Harris NL, et al, pp 188–190. IARC, Lyon, France, 2008.
cell leukemia: A study of the National Cancer Institute of Canada Clinical Trials Group. 40. Schwarzmeier JD, Hilgarth M, Nguyen ST, et al: Inadequate production of hematopoi-
J Natl Cancer Inst 80:765–769, 1988. etic growth factors in hairy cell leukemia: Up-regulation of interleukin 6 by recombi-
9. Grever M, Kopecky K, Foucar MK, et al: Randomized comparison of pentostatin versus nant IFN-alpha in vitro. Cancer Res 56:4679–4685, 1996.
interferon alfa-2a in previously untreated patients with hairy cell leukemia: An inter- 41. Shehata M, Schwarzmeier JD, Hilgarth M, et al: TGF-beta1 induces bone marrow reti-
group study. J Clin Oncol 13:974–982, 1995. culin fibrosis in hairy cell leukemia. J Clin Invest 113:676–685, 2004.
10. Piro LD, Carrera CJ, Carson DA, et al: Lasting remissions in hairy-cell leukemia 42. Hoffman MA: Clinical presentations and complications of hairy cell leukemia. Hematol
induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117–1121, Oncol Clin North Am 20:1065–1073, 2006.
1990. 43. Frassoldati A, Lamparelli T, Federico M, et al: Hairy cell leukemia: A clinical review
11. Tallman MS, Hakimian D, Variakojis D, et al: A single cycle of 2-chlorodeoxyadenosine based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative
results in complete remission in the majority of patients with hairy cell leukemia. Blood Group for Hairy Cell Leukemia. Leuk Lymphoma 13:307–316, 1994.
80:2203–2209, 1992. 44. Lembersky BC, Golomb HM: Hairy cell leukemia: Clinical features and therapeutic
12. Goodman GR, Burian C, Koziol JA, et al: Extended follow-up of patients with hairy cell advances. Cancer Metastasis Rev 6:283–300, 1987.
leukemia after treatment with cladribine. J Clin Oncol 21:891–896, 2003. 45. Morrison V: Infections in patients with leukemia and lymphoma. Cancer Treat Res
13. Zenhausern R, Schmitz SF, Solenthaler M, et al: Randomized trial of daily versus weekly 161:319–349, 2014.
administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: A mul- 46. Seymour JF, Kurzrock R, Freireich EJ, et al: 2-chlorodeoxyadenosine induces durable
ticenter phase III trial (SAKK 32/98). Leuk Lymphoma 50:1501–1511, 2009. remissions and prolonged suppression of CD4+ lymphocyte counts in patients with
14. Robak T, Jamroziak K, Gora-Tybor J, et al: Cladribine in a weekly versus daily schedule hairy cell leukemia. Blood 83:2906–2911, 1994.
for untreated active hairy cell leukemia: Final report from the Polish Adult Leukemia 47. Tadmor T: Purine analog toxicity in patients with hairy cell leukemia. Leuk Lymphoma
Group (PALG) of a prospective, randomized, multicenter trial. Blood 109:3672–3675, 52 (Suppl 2):38–42, 2011.
2007. 48. Herold CJ, Wittich GR, Schwarzinger I, et al: Skeletal involvement in hairy cell leuke-
15. Lauria F, Cencini E, Forconi F: Alternative methods of cladribine administration. Leuk mia. Skeletal Radiol 17:171–175, 1988.
Lymphoma 52 (Suppl 2):34–37, 2011. 49. Westbrook CA, Golde DW: Autoimmune disease in hairy-cell leukaemia: Clinical syn-
16. Habermann TM, Andersen JW, Cassileth PA, et al: Sequential administration of recom- dromes and treatment. Br J Haematol 61:349–356, 1985.
binant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. 50. Tadmor T, Polliack A: Unusual clinical manifestations, rare sites of involvement, and the
Br J Haematol 80:466–471, 1992. association of other disorders with hairy cell leukemia. Leuk Lymphoma 52 (Suppl 2):
17. Saven A, Burian C, Adusumalli J, et al: Filgrastim for cladribine-induced neutropenic 57–61, 2011.
fever in patients with hairy cell leukemia. Blood 93:2471–2477, 1999. 51. Anderson LA, Engels EA: Autoimmune conditions and hairy cell leukemia: An explor-
18. Golomb HM: Hairy cell leukemia: Treatment successes in the past 25 years. J Clin Oncol atory case-control study. J Hematol Oncol 3:35, 2010.
26:2607–2609, 2008. 52. Hauswirth AW, Skrabs C, Schutzinger C, et al: Autoimmune hemolytic anemias, Evans’
19. Grever MR, Blachly JS, Andritsos LA: Hairy cell leukemia: Update on molecular profil- syndromes, and pure red cell aplasia in non-Hodgkin lymphomas. Leuk Lymphoma
ing and therapeutic advances. Blood Rev 28:197–203, 2014. 48:1139–1149, 2007.
20. Chandran R, Gardiner SK, Smith SD, et al: Improved survival in hairy cell leukaemia 53. Mainwaring CJ, Walewska R, Snowden J, et al: Fatal cold anti-i autoimmune haemolytic
over three decades: A SEER database analysis of prognostic factors. Br J Haematol anaemia complicating hairy cell leukaemia. Br J Haematol 109:641–643, 2000.
163:407–409, 2013. 54. Moullet I, Salles G, Dumontet C, et al: Sever immune thrombocytopenic purpura and
21. Teodorescu M, Engebjerg MC, Johansen P, et al: Incidence, risk of infection and sur- haemolytic anaemia in a hairy-cell leukaemia patient. Eur J Haematol 54:127–129, 1995.
vival of hairy cell leukaemia in Denmark. Dan Med Bull 57:A4216, 2010. 55. Ozkan A, Taskapilioglu O, Bican A, et al: Hairy cell leukemia presenting with Guil-
22. Sigal DS, Sharpe R, Burian C, et al: Very long-term eradication of minimal residual lain-Barre syndrome. Leuk Lymphoma 48:1048–1049, 2007.
disease in patients with hairy cell leukemia after a single course of cladribine. Blood 56. Jansen J, Hermans J: Splenectomy in hairy cell leukemia: A retrospective multicenter
115:1893–1896, 2010. analysis. Cancer 47:2066–2076, 1981.
23. Tallman MS: Implications of minimal residual disease in hairy cell leukemia after clad- 57. Sharpe RW, Bethel KJ: Hairy cell leukemia: Diagnostic pathology. Hematol Oncol Clin
ribine using immunohistochemistry and immunophenotyping. Leuk Lymphoma 52 North Am 20:1023–1049, 2006.
(Suppl 2):65–68, 2011. 58. Wang XJ, Kim A, Li S: Immunohistochemical analysis using a BRAF V600E mutation
24. Hall RD, Kudchadkar RR: BRAF mutations: Signaling, epidemiology, and clinical expe- specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia.
rience in multiple malignancies. Cancer Control 21:221–230, 2014. Int J Clin Exp Pathol 7:4323–4328, 2014.
25. Dietrich S, Glimm H, Andrulis M, et al: BRAF inhibition in refractory hairy-cell leuke- 59. Seetharam A, Perrillo R, Gish R: Immunosuppression in patients with chronic hepatitis
mia. N Engl J Med 366:2038–2040, 2012. B. Curr Hepatol Rep 13:235–244, 2014.
26. Rosenberg JD, Burian C, Waalen J, et al: Clinical characteristics and long-term outcome 60. Golomb HM: Hairy cell leukemia: Lessons learned in twenty-five years. J Clin Oncol
of young hairy cell leukemia patients treated with cladribine: A single-institution series. 1:652–656, 1983.
Blood 123:177–183, 2014. 61. Matsushita K, Margulies I, Onda M, et al: Soluble CD22 as a tumor marker for hairy cell
27. Dores GM, Matsuno RK, Weisenburger DD, et al: Hairy cell leukaemia: A heteroge- leukemia. Blood 112:2272–2277, 2008.
neous disease? Br J Haematol 142:45–51, 2008. 62. Grever MR: How I treat hairy cell leukemia. Blood 115:21–28, 2010.
28. Orsi L, Delabre L, Monnereau A, et al: Occupational exposure to pesticides and lym- 63. Habermann TM: Splenectomy, interferon, and treatments of historical interest in hairy
phoid neoplasms among men: Results of a French case-control study. Occup Environ cell leukemia. Hematol Oncol Clin North Am 20:1075–1086, 2006.
Med 66:291–298, 2009. 64. Piris MA, Foucar K, Mollejo M, et al: Splenic B-cell lymphoma/leukaemia, unclassi-
29. Hisada M, Chen BE, Jaffe ES, et al: Second cancer incidence and cause-specific mor- fiable, in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed
tality among 3104 patients with hairy cell leukemia: A population-based study. J Natl 4, edited by Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J,
Cancer Inst 99:215–222, 2007. Vardiman JW, pp 191–193. IARC, Lyon, France, 2008.
30. Matutes E: Immunophenotyping and differential diagnosis of hairy cell leukemia. 65. Kreitman RJ, Wilson W, Calvo KR, et al: Cladribine with immediate rituximab for the treat-
Hematol Oncol Clin North Am 20:1051–1063, 2006. ment of patients with variant hairy cell leukemia. Clin Cancer Res 19:6873–6881, 2013.
31. Forconi F, Sozzi E, Cencini E, et al: Hairy cell leukemias with unmutated IGHV genes 66. Robak T: Hairy-cell leukemia variant: Recent view on diagnosis, biology and treatment.
define the minor subset refractory to single-agent cladribine and with more aggressive Cancer Treat Rev 37:3–10, 2011.
behavior. Blood 114:4696–4702, 2009. 67. Naik RR, Saven A: My treatment approach to hairy cell leukemia. Mayo Clin Proc
32. Forconi F: Hairy cell leukaemia: Biological and clinical overview from immunogenetic 87:67–76, 2012.
insights. Hematol Oncol 29:55–66, 2011. 68. Golomb HM: Fifty years of hairy cell leukemia treatments. Leuk Lymphoma 52 (Suppl 2):
33. Arons E, Kreitman RJ: Molecular variant of hairy cell leukemia with poor prognosis. 3–5, 2011.
Leuk Lymphoma 52 (Suppl 2):99–102, 2011. 69. Chadha P, Rademaker AW, Mendiratta P, et al: Treatment of hairy cell leukemia with
34. Tiacci E, Trifonov V, Schiavoni G, et al: BRAF mutations in hairy-cell leukemia. N Engl 2-chlorodeoxyadenosine (2-CdA): Long-term follow-up of the Northwestern Univer-
J Med 364:2305–2315, 2011. sity experience. Blood 106:241–246, 2005.

Kaushansky_chapter 93_p1553-1562.indd 1560 9/18/15 3:47 PM